Annals of Hematology

, Volume 97, Issue 8, pp 1445–1452 | Cite as

Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma

  • Satoshi Yamasaki
  • Dai Chihara
  • Sung-Won Kim
  • Koji Izutsu
  • Kouji Iwato
  • Takahiro Fukuda
  • Naoyuki Uchida
  • Itsuto Amano
  • Hideyuki Nakazawa
  • Junya Kuroda
  • Hisako Hashimoto
  • Tatsuo Ichinohe
  • Yoshinobu Kanda
  • Yoshiko Atsuta
  • Junji Suzumiya
  • Ritsuro Suzuki
Original Article


Rituximab has been shown to improve outcomes in patients with B-cell lymphoma. However, patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) still have a poor prognosis, and the choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains controversial in these patients. We retrospectively analyzed the risk factors for outcomes in 162 R/R MCL patients who received autologous (n = 111) or allogeneic (n = 51) HCT between 2004 and 2014. The median overall survival (OS) rates were 48 and 65 months in the autologous and allogeneic HCT groups, respectively (P = 0.20). Significant risk factors for overall survival in R/R MCL patients after autologous HCT were > 60 years of age at HCT (P = 0.017), higher score of HCT-specific comorbidity index at HCT (P = 0.033), and receiving MCEC (ranimustine + carboplatin + etoposide + cyclophosphamide) regimen (P = 0.017), while higher performance status at HCT (P = 0.011) and longer interval from diagnosis to HCT (P = 0.0054) were risk factors after allogeneic HCT. Strategies that carefully select R/R MCL patients for autologous HCT may allow the identification of individuals suitable for allogeneic HCT.


Mantle cell lymphoma Autologous hematopoietic cell transplantation Allogeneic hematopoietic cell transplantation relapsed or refractory 



We appreciate the patients and clinical staff for their participation in the study. We are very grateful to the Japanese Data Center for Hematopoietic Cell Transplantation for data management and to the Clinical Research Institute of Kyushu Medical Hospital for their editorial support. The Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED) supported this work. We thank Edanz Group ( for editing a draft of this manuscript.

Compliance with ethical standards

This study was approved by the data management committee of the Japanese Society for Hematopoietic Cell Transplantation and the Institutional Review Board of Kyushu Medical Center.

Informed consent

The TRUMP databese includes physician-reviewed data. Observational studies base on the TRUMP databese are performed with an informed consent.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 105:2677–2684CrossRefPubMedGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, Kato K, Tabuchi K, Tsuchida M, Morishima Y, Mitamura M, Kawa K, Kato S, Nagamura T, Takanashi M, Kodera Y (2007) Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol 86:269–274CrossRefPubMedGoogle Scholar
  4. 4.
    Atsuta Y (2016) Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3–10CrossRefPubMedGoogle Scholar
  5. 5.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828PubMedGoogle Scholar
  6. 6.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956CrossRefPubMedGoogle Scholar
  7. 7.
    Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMedGoogle Scholar
  8. 8.
    Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced intensity conditioning regimen workshop: defining the dose spectrum-report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S, Vitolo U, Dreyling M, Hermine O, European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2015) The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 29:464–473CrossRefPubMedGoogle Scholar
  10. 10.
    Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK (2013) Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 19:1403–1406CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM (2013) Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 19:625–631CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN (2014) Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 32:273–281CrossRefPubMedGoogle Scholar
  13. 13.
    Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI, Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT) (2010) Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16:1419–1427CrossRefPubMedGoogle Scholar
  14. 14.
    Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF (2009) Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144–4152CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535–3542CrossRefPubMedGoogle Scholar
  16. 16.
    Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M, German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558–565CrossRefPubMedGoogle Scholar
  17. 17.
    Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd HW, Cabeçadas J, Campo E, Cogliatti S, Hansmann ML, Kluin PM, Kodet R, Krivolapov YA, Loddenkemper C, Stein H, Möller P, Barth TE, Müller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken JH, Wacker HH, Unterhalt M, Hiddemann W, Dreyling M, European MCL Network (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network. J Hematop 2:103–111CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wu J, Liu C, Tsui ST, Liu D (2016) Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9:80CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wu J, Zhang M, Liu D (2016) Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 9:21CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang Z, Wu Z, Liu Y, Han W (2017) New development in CAR-T cell therapy. J Hematol Oncol 10:53CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Davids MS (2017) Targeting BCL-2 in B-cell lymphomas. Blood 130:1081–1088CrossRefPubMedGoogle Scholar
  22. 22.
    Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M, Trial Investigators SPRINT (2018) Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. Br J Haematol 180:224–235CrossRefPubMedGoogle Scholar
  23. 23.
    Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A (2018) Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol in pressGoogle Scholar
  24. 24.
    Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M (2012) Reduced intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23:2695–2703CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Satoshi Yamasaki
    • 1
  • Dai Chihara
    • 2
  • Sung-Won Kim
    • 3
  • Koji Izutsu
    • 4
  • Kouji Iwato
    • 5
  • Takahiro Fukuda
    • 3
  • Naoyuki Uchida
    • 4
  • Itsuto Amano
    • 6
  • Hideyuki Nakazawa
    • 7
  • Junya Kuroda
    • 8
  • Hisako Hashimoto
    • 9
  • Tatsuo Ichinohe
    • 10
  • Yoshinobu Kanda
    • 11
  • Yoshiko Atsuta
    • 12
  • Junji Suzumiya
    • 13
  • Ritsuro Suzuki
    • 13
  1. 1.Department of Hematology and Clinical Research InstituteNational Hospital Organization Kyushu Medical CenterFukuokaJapan
  2. 2.Department of Internal MedicineThe University of New MexicoAlbuquerqueUSA
  3. 3.Division of Hematopoietic Stem Cell TransplantationNational Cancer Center HospitalTokyoJapan
  4. 4.Department of HematologyFederation of National Public Service Personnel Mutual Aid Associations Toranomon HospitalTokyoJapan
  5. 5.Department of HematologyHiroshima Red Cross Hospital and Atomic-bomb Survivors HospitalHiroshimaJapan
  6. 6.Department of Respiratory, Allergy, and HematologyNara Medical University HospitalNaraJapan
  7. 7.Division of Hematology, Department of Internal MedicineShinshu University School of MedicineMatsumotoJapan
  8. 8.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  9. 9.Department of Hematology and Cell therapyKobe General Hospital and Institute of Biomedical Research and InnovationKobeJapan
  10. 10.Department of Hematology and Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  11. 11.Division of Hematology, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  12. 12.Department of Healthcare AdministrationNagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell TransplantationNagoyaJapan
  13. 13.Department of Oncology and HematologyShimane University HospitalIzumoJapan

Personalised recommendations